Result of General Meeting
London, UK, 1 February 2010 – Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company, is pleased to announce that at the General Meeting of the Company held today all of the resolutions were duly passed by shareholders, including Resolution 1 which was passed by a poll with 300,541,363 in favour and 10,000 against.
Application has been made for the 1,333,390,207 placing, subscription and offer shares of 1p each to be admitted to trading on AIM. It is expected that admission of these shares (“Admission”) will become effective and dealings will commence on AIM at 08.00 am on 2 February 2010. Following Admission, Invesco Asset Management Limited will have an interest in 955,179,756 shares of 1p each representing approximately 43.92 per cent. of the enlarged issued share capital of the Company.
- Ends -
Enquiries:
Lombard Medical Technologies PLC
Tel: +44 (0) 1235 750 800
Simon Neathercoat, Non-executive Chairman
John Barry Rush, Chief Executive Officer
Tim Hall, Finance Director
Evolution Securities Limited (Nominated Adviser and Broker to the Company)
Barry Saint
Tim Redfern
Esther Lee Tel: +44 (0) 20 7071 4300
Financial Dynamics Tel: +44 (0) 20 7831 3113
Jonathan Birt
Susan Quigley
Notes to editors
About Lombard Medical
Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment of vascular disease. The Company’s lead product, Aorfix™, is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAAs), a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death.
Approximately 4.5 million people are living with AAA in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for the treatment of AAA is currently worth approximately $900 million and is expected to grow to around $1.6 billion by 2015. Aorfix™ has CE Mark approval in the EU and is currently being commercialised in the EU, with a pivotal clinical trial ongoing in the USA.
The Company is headquartered in Oxfordshire, with operations in Prestwick, Ayrshire and Boston, USA.
Further background on the Company can be found at www.lombardmedical.com.